Similar articles

• Systemic eight-cycle anti-CD20 monoclonal antibody (rituximab) therapy in primary cutaneous B-cell lymphomas--an applicational observation.

  Gellrich S, Muche JM, Wilks A, Jasch KC, Voit C, Fischer T, Audring H, Sterry W. Gellrich S, et al. Br J Dermatol. 2005 Jul;153(1):167-73. doi: 10.1111/j.1365-2133.2005.06659.x. Br J Dermatol. 2005. PMID: 16029344 Review.
• Favorable outcome of primary cutaneous marginal zone lymphoma treated with intralesional rituximab.

  Kyrtsonis MC, Siakantaris MP, Kalpadakis C, Dimopoulou MN, Vassilakopoulos TP, Kontopidou FN, Antoniou C, Korkolopoulou P, Panayiotidis P, Pangalis GA. Kyrtsonis MC, et al. Eur J Haematol. 2006 Oct;77(4):300-3. doi: 10.1111/j.1600-0609.2006.00720.x. Epub 2006 Jul 19. Eur J Haematol. 2006. PMID: 16856917
• Pediatric primary cutaneous marginal zone B-cell lymphoma treated with intralesional rituximab.

  Park MY, Jung HJ, Park JE, Kim YC. Park MY, et al. Eur J Dermatol. 2010 Jul-Aug;20(4):533-4. doi: 10.1684/ejd.2010.0987. Epub 2010 Jun 14. Eur J Dermatol. 2010. PMID: 20542839 No abstract available.
• Remission of breakthrough hepatitis in chronic hepatitis B patients on lamivudine.

  Koike K. Koike K. J Gastroenterol. 2002;37(11):988-90. doi: 10.1007/s005350200167. J Gastroenterol. 2002. PMID: 12483259 No abstract available.
• Conjunctival malt lymphoma successfully treated with single agent rituximab therapy.

  Salepci T, Seker M, Kurnaz E, Guler DO, Bilici A, Dane F, Aliustaoglu M, Atesoglu EB, Gumus M, Yaylaci M. Salepci T, et al. Leuk Res. 2009 Mar;33(3):e10-3. doi: 10.1016/j.leukres.2008.05.018. Epub 2008 Jul 23. Leuk Res. 2009. PMID: 18653234 Review. No abstract available.